BiPar Sciences is a cancer focused company that’s developing a PARP inhibitor (BSI-201) licensed from Crimson Pharma (now defunct). The company has been around for 4+ years and is still trying to generate data that is compelling enough to get a deal done. A glioblastoma trial was completed last year, but no results have been released. Currently, the company has a few trials ongoing: ovarian, uterine and triple negative breast cancer.

The grapevine told us the company was even considering selling their lead back in 08. With no takers, existing investors came in and rescued BiPar with a recent $20M cash infusion.

BiPar has swallowed quite a bit of cash over the last 4+ years:

-$13M (2004)

-$5M (2006)

-$35M (2007)

-$20M (2009)

You would think that a novel target and NME with a good response could entice a buyer. This obviously hasn’t been the case – because there hasn’t been a solid response – and now Domain & Co have stepped in to take an additional risk.

Here’s a list of all the ongoing trials.

Management

Hoyoung Huh – President, CEO

Barry Sherman – Development

Charles Bradley – Clinical Development

Deborah Thomas – Regulatory Affairs

Sunil Patel – Corporate Development and Marketing

John Schembri – CFO

Investors

Domain Associates

Canaan Partners

Vulcan Partners

Polytechnos

Quantum Technology Partners

Asset Management Company

Lighthouse Capital Partners

Related Posts